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Abstract
Background:  The incidence and prevalence of diabetes are increasing all over the world.
Complications of diabetes constitute a burden for the individuals and the whole society.
Methods: In the present paper, ordinary differential equations and numerical approximations are
used to monitor the size of populations of diabetes with and without complications.
Results: Different scenarios are discussed according to a set of parameters and the dynamical
evolution of the population from the stage of diabetes to the stage of diabetes with complications
is clearly illustrated.
Conclusions: The model shows how efficient and cost-effective strategies can be obtained by
acting on diabetes incidence and/or controlling the evolution to the stage of complications.
Background
It is now commonly admitted that diabetes is sweeping
the globe as a silent epidemic largely contributing to the
growing burden of non-communicable diseases and
mainly encouraged by decreasing levels of activity and
increasing prevalence of obesity. The recent reports
released by the World Health Organization [1] and the
International Diabetes Federation [2] are alarming. In
2003, it was estimated that 194 million people were dia-
betic, representing a global prevalence exceeding 3%
(5.1% for those aged 20 to 79) of the world population.
The trend is increasing and the number is expected to
reach 333 million (6.3%) by the year 2025. Moreover, for
the first time, an estimation of 314 million (8.2%) is
given for people in the pre-diabetic stage which consti-
tutes a compartment from which at least one third will
evolve to the diabetic stage after 10 years.
Dramatic increase have occurred in both prevalence and
incidence of diabetes globally, especially with the new
threshold proposed by the Expert Committee on the diag-
nosis and classification of diabetes mellitus in 1997 [3]
and adopted by the World Health Organization. But it is
worth noting the growing part of developing countries as
stressed by many authors [4-6] and summarized in Table
1 for the ten leading countries [2]. In general, two forms
of diabetes are considered: Type 1 diabetes, also known as
Insulin Dependent Diabetes Mellitus (IDDM), affecting
people under the age of 40 and representing 10 to 15% of
the diabetic population, and Type 2 diabetes formerly
known as Non Insulin Dependent Diabetes Melli-
tus(NIDDM), representing the major part (85–90%).
However, with the growing epidemic of obesity in all age
categories, it is expected that in ten years time, there will
be more children with type 2 than with type 1 [7].
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Indeed, Obesity is another burden challenging the health
authorities in almost all countries(high-income and low
income alike), although with some variations within and
between countries. In the United States, obesity preva-
lence has increased from 30% in the sixties to more that
60% as indicated by a recent study on obesity and the risk
of heart failure which considered hypertension, diabetes
and myocardial infarction, stressing that obesity pro-
motes all three, and these promote heart failure [8]. In
Prance, the proportion of obese children has grown from
12% in 1990 to 16% in 2000, which lead the health
authorities to launch the Programme National Nutrition
Santé in 2001 [9]. However, a special attention must be
given to the contrasting effect in developing countries
where obesity often coexists in the same population with
chronic malnutrition and the burden of deaths and disa-
bility caused by non-communicable diseases outweighs
that imposed by long-standing communicable diseases
[1,10]. This global diagnosis being given, it is essential to
stress that much of the cost of diabetes treatment is attrib-
utable to long term complications, such as blindness, kid-
ney failure, heart disease, amputations and their
economic and social consequences (care, hospitalization,
absenteeism,...). Indeed, diabetes is:
– the leading cause of end-stage kidney failure necessitat-
ing dialysis or transplantation,
– the leading cause of blindness in people of working age,
– the leading cause of amputation,
– the first cause -with other risk factors- of mortality and
morbidity by cardiovascular diseases.
The burden of diabetes and its complications
The exact costs of diabetes are not easy to pin down but
estimations can be obtained according to three levels:
1. Cost directly related to the diagnosis and management
of diabetes without complications. This includes the in-
patient and out-patient care, means of treatment by insu-
lin or tablets and the equipment of self control (blood
and urine testing).
2. Costs generated by complications of diabetes. These are
difficult to quantify because diabetes is linked to micro
and macro vascular diseases such as heart disease, kidney
failure, eye disease and amputation. Moreover, diabetes
may add a cost of care by complicating other unrelated
medical situations like infections, accidents and surgery.
3. Indirect costs correlated to the quality of life and the
economic productivity which can be somehow estimated
by the degree of disability.
In order to facilitate meaningful comparisons across
world regions, costs are often expressed in international
dollars (an international dollar has the same purchasing
power as one US dollar has in the USA) and cost-effective-
ness is measured in terms of years lived with disability
(YLD) or disability adjusted life years (DALY) [11,12].
Studies in different countries have shown that diabetes is
a costly disease accounting for between 2.5 and 15% of
the total healthcare expenditure. For the age category 20–
79, the world annual direct cost is estimated to be over
153 billion and expected to double in 2025 [2,13-16].
According to the National Institute of Diabetes and Diges-
tive Kidney Disease (NIDDK) and the American Diabetes
Association, diabetes was the sixth leading cause of death
in 1999 with a direct cost of $44 billion and an indirect
cost of $54 billion annually. In 2002, the direct and indi-
rect cost totaled $132 billion [14]. In France, an estima-
tion of $5.7 billion was given for the direct cost of
diabetes [5], whereas, an equivalent cost of £5.2 billion,
representing approximately 9% of the annual national
health service (NHS) budget, was given for UK in 2000
Table 1: Estimated numbers of diabetics (in Million)
Country 2003 2025
India 35.5 73.5
China 23.8 46.1
United States 16 23.1
Russia 9.7 10.7
Japan 6.7 7.1
Germany 6.3 7.1
Pakistan 6.2 11.6
Brazil 5.7 10.7
Mexico 4.4 9
Egypt 3.9 7.8BioMedical Engineering OnLine 2004, 3 http://www.biomedical-engineering-online.com/content/3/1/20
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[15]. The burden affects also developing countries as
stressed by the different authors who attended the seventh
congress of the Pan-African diabetes study group in 2001
[16] and the Metabolic Syndrome type II Diabetes and
Artherosclerosis Congress in 2004 [17]. In these, coun-
tries, until recently, it was widely believed that economic
development was a necessary prerequisite for improving a
population health status and the health was often classi-
fied as a non productive sector. Now, politicians and
health policy makers are timidly recognizing that invest-
ing in people's health is a necessary condition for eco-
nomic development but energetic decisions are needed
for the adoption of urgent and consequent strategies. The
need for such strategies is enhanced by the fact that risk
factors like cholesterol, tobacco, blood pressure, and
obesity are no more a specificity of industrialized coun-
tries, they are becoming more prevalent in developing
nations, where they double the burden of infectious dis-
eases that have always afflicted poorer countries [10].
The literature dealing with modeling for diabetes is
mainly concerned with glucose and insulin dynamics
[6,18-20], the epidemiology of the disease [21-23] and
economic cost and risk models [24-29]. In previous
papers, the authors considered continuous and matrix
models for age structured populations of diabetics [30,31]
and Dynamics of a disabled population in Morocco [32].
In the present paper, while stressing the growing burden
of disease caused by diabetes and its complications, a
model is proposed to monitor the size of the diabetic pop-
ulation and to deal with the evolution from the stage of
diabetes without complications to the stage of diabetes
with complications. Parameters can be handled to illus-
trate the effect of an increasing or decreasing incidence of
diabetes and its complications. Consequently, different
strategies can be adopted. The main purpose is to show
that investment in primary health care is a necessary and
cost-effective strategy that allow to control the incidences
of diabetes and its complications and hence, to convince
policy makers that bold decisions must be taken for a sus-
tainable development which ensures better quality of life
and well-being for the present and future generations of
humans.
Methods
The mathematical model
Suppose that C = C(t) and D = D(t) represent the numbers
of diabetics with and without complications, respectively,
and let N = N(t) = C(t) + D(t) denote the size of the pop-
ulation of diabetics at time t (see Nomenclature). Then, as
was noted earlier, N(t) ~ 3% of the world population. Let
I  = I(t) denote the incidence of diabetes mellitus. The
model parameters to be incorporated are µ (the natural
mortality rate), λ  (the probability of a diabetic person
developing a complication), γ (the rate at which compli-
cations are cured), ν (the rate at which diabetic patients
with complications become severely disabled) and δ (the
mortality rate due to complications).
A schematic representation of the model is shown in Fig-
ure 1.
The diagram shows that I = I(t) cases are diagnosed in a
time interval of length t and are assumed to have no com-
plications upon diagnosis. In that same time interval, the
number of sufferers without complications, D = D(t), is
seen to decrease by the amounts µD (natural mortality)
and λD (sufferers who develop complications), and to
increase by the amount γC (sufferers whose complications
are cured). During this time interval, the number of dia-
betics with complications is increased by the afore-men-
tioned amount γC  and by the amount µC  (natural
mortality), νC (patients who become severely disabled
and whose disabilities cannot be cured) and δC (those
who die from their complications).
These rates of change are formalized by the ordinary dif-
ferential equations (ODEs)
which, since N(t) = D(t) + C(t), give rise to the initial-
value problem (IVP)
C'(t) = -(λ + θ)C(t) + λN(t), t > 0; C(0) = C0  (1)
N'(t) = I(t) - (ν + δ)C(t) - µN(t), t > 0; N(0) = N0  (2)
where θ = γ + µ + ν + δ,   and  C0, N0 are the
initial values of C(t) and N(t), respectively.
In the case when the probability of a diabetic person
developing a complication, λ, is constant, the model
The mathematical model Figure 1
The mathematical model
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equations (1), (2) are linear in C(t) and N(t): this linear
model will be discussed in the following paragraph. The
non-linear model corresponding to a variable λ will be
considered by the authors in another paper more devoted
to numerical analysis.
The linear case
The critical point and its stability property
The probability of developing a complication, λ, will be
estimated to have the constant value
The initial-value problem (1), (2) may consequently be
written in matrix-vector form as
x'(t) = Ax(t) + b(t), t > 0;x(0) = X0  (4)
in which
Suppose that I is the steady-state value of the incidence,
then the model reaches its critical point when dC/dt and
dN/dt given in (1) and (2) vanish simultaneously, that is
when
λN - (λ + θ)C = 0,  (6)
I - µN - (ν + δ)C = 0.  (7)
Solving (6) and (7)gives
and
The eigenvalues of the matrix A, χ1, χ2, are the roots of the
quadratic equation (the characteristic equation)
χ2 + (λ + θ + µ)χ + µ(λ + θ) + λ(ν + δ) = 0.  (9)
The discriminant, ∆, of this equation is given by
∆ = (λ + θ + µ)2 - 4 [µ(λ + θ) + λ(ν + δ)]
and, recalling that θ = ν + µ + δ + γ it follows that
∆ <λ + µ + δ + γ + 2ν.
Solving (9) gives
and it is then easy to check that, when the parameters of
the model are such that
(a) ∆ > 0, χ1, χ2 are both real and negative;
(b) ∆ = 0, χ1 = χ2 are real and negative;
(c) ∆ < 0, χ1 and χ2 are complex conjugate with negative
real parts.
it may be concluded, therefore, that the critical point (C*,
N*) of (1), (2), given by (8), is stable.
Numerical solution and stability
It may be shown that the solution x(t) of the IVP (4) sat-
isfies the recurrence relation
where l > 0 is an increment in t (the time step). This recur-
rence relation may be used to generate x(tn + 1) in terms of
x(tn), thus monitoring C(t) and N(t) at the discrete points
t = tn = nl(n = 0, 1, 2, ...).
One very simple way of estimating x(t + l) is to approxi-
mate to second order the integral in (11) by the trapezoi-
dal rule, viz.
and then to replace, also to second order, exp(lA) in (11)
and (12) by its (1,1) Padé approximant
exp(lA) = (E - 1/2lA)-1 (E + 1/2lA)  (13)
where E is the identity matrix of order two.
Denoting by Xn the numerical approximation to x(tn) cal-
culated using (11), (13), it may be shown, by substituting
(12) with (13) in (11) and then by pre-multiplying by (E
- 1/2lA), that
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(E - 1/2lA)Xn + 1 = (E + 1/2lA)Xn  (14)
+
1/2l[(E - 1/2lA)bn + 1 + (E + 1/2lA)bn];n = 0, 1, 2, ...
where Xn = (Cn, Nn)T, T denoting transpose, and bn = (0,
In)T with In = I(tn). It may then be shown that Cn + 1 and Nn
+ 1 (n = 0, 1, 2,...) may be determined by solving the alge-
braic equations given by
(Method 1) (1 + 1/2l(λ + θ))Cn + 1 - 1/2lλNn + 1 =
[1 - 1/2l(λ + θ)]Cn + 1/2lλNn - 1/4l2λ(In + 1 - In) ( 1 5 )
and
1/2l(ν + δ)Cn + 1 + (1 + 1/2lµ)Nn + 1 =
-1/2l(ν + δ)Cn + (1 - 1/2lµ)Nn
+1/2l(1 + lµ)In + 1 + 1/2l(1 - lµ)In  (16)
assuming convergence, Cn + 1 = Cn = C, Nn + 1 = Nn = N and
In + 1 = In = I, say, then equations (15) and (16) become
(λ + θ)C - λN = 0,  (17)
(ν + δ)C + µN = I, ( 1 8 )
respectively. Obviously (17) and (18) are the same as (6)
and (7) and so the fixed point (C+, N+) of the numerical
solution sequence (Cn, Nn), n = 0, 1, 2,... is the same as the
critical point (C*, N*) of the linear initial value-problem.
For comparison purpose, the IVP (1), (2) was also solved
using the well-known Euler method (a first-order
method) given by
(Method 2) Cn + 1 = [1 - l(λ + θ)]Cn + lλNn  (19)
Nn + 1 = -l(ν + δ)Cn + (1 - lµ) + lINn  (20)
The method1 is unconditionally stable whereas the Euler
method is conditionally stable provided ([33])
Numerical experiments
Taking I(t) = I to be constant equations (15) and (16) sim-
plify to
(1 + 1/2l(λ + θ))Cn + 1 - 1/2lλNn + 1 =
[1 - 1/2l(λ + θ)]Cn + 1/2lλNn  (22)
1/2l(ν + δ)Cn + 1 + (1 + 1/2lµ)Nn + 1 =
-1/2l(ν + δ)Cn + (1 - 1/2lµ)Nn + lI, ( 2 3 )
respectively, for n = 0, 1, 2, .... In the numerical experi-
ments, I was given the value 6.106yr-1 and the parameters
ν, δ, µ, γ, were given the value shown in Table 2. the criti-
cal values of C and N were then calculated from (8) and
were found to be
C* = 47000000 and N* = 61100000.  (24)
Using Matlab, four numerical experiments were carried
out taking as initial conditions
C0 = C* ± 500 and N0 = N* ± 500.  (25)
A time step of l = 0.01yr-1 was used and the solution to the
IVP (1), (2) was computed by solving (22), (23) for n = 0,
1, 2, .... Using all combinations of initial conditions, the
computed solution converged to the values of C* and N*
given in (24). By way of example, the fixed points, C+ and
N+, to which the numerical solution converged are shown
in Table 3.
The initial conditions in (25) are close to the steady-state
solutions  C* and N*. Other initial conditions, further
from C* and N*, will converge to the same values of C+
and N+ for the same value of l, though these values will be
reached at different times.
Retaining the parameters values shown in Table 2 the
effect of the choice of time step was monitored in a series
of 11 further experiments. The fixed-point values, C+ and
N+ to which convergence occurred are shown in Table 3,
where it may be seen that, for the larger values of l (l ≥
0.5yr), there is very close agreement with the critical-point
values given in (24).
For l ≤ 2yr (approximately), the two methods give similar
results but for l > 2.5yr (approximately (21)) the Euler
method diverged. The values of C+ and N+ using Euler
method are given in Table 3.
Table 2: Parameter vlaues used in numerical experiments
Parameter Value yr-1
ν 0.05
δ 0.05
µ 0.02
γ 0.08 or 0
l <
++ () ++ + () −+ ()
()
4
4
21
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It may be concluded from these results that the Euler
method may be used with confidence if the diabetic pop-
ulation is to be monitored at time intervals up to approx-
imately two years using the linear model (1), (2).
However, to monitor the population less frequently the
numerical method (Method 1) should be used.
Results and discussion
Nine scenarios were considered (Low-Low, Low-Medium,
Low-High, Medium-Low, Medium-Medium, Medium-
High, High-Low, High-Medium, and High-High) by com-
bining the levels of incidence of diabetes and its compli-
cations. For instance, High-High refers to a high incidence
of diabetes and high incidence of complications. These
combinations are given by different values of the parame-
ters I for incidence of diabetes and A for incidence of com-
plications. The model shows clearly the differences in the
global number of diabetics (N) and the number of diabet-
ics with complications(C) as illustrated by Tables 4. The
number of diabetics resulting from a strategy with high
incidence may be reduced by half if a strategy with
medium incidence is applied during a dozen of years. A
further reduction by three can be obtained by a strategy
with low incidence. But, more importantly, the rate of
complications reaches 78% in a high strategy of complica-
tions, it can be reduced to 63% (respectively 53%) with a
medium (respectively a low) strategy of complications.
Now, are we really able to act on these incidences and
how? Precise answers have been given at different levels.
For the incidence of diabetes, worldwide, it is now com-
monly admitted that efforts must be conjugated to reverse
or at least to attenuate its growing trend, otherwise, health
authorities will be unable to provide care and treatments
for millions of people who will be affected by diabetes in
the future [1,2,7,16,34]. Propositions are mainly directed
towards risk factors like obesity, tobacco inactivity, alco-
hol, blood pressure, cholesterol, inheritance and diet hab-
its in general [4,6,35]. Many authors have dealt with
complications [1,2,36,37]. The strategy can be summa-
rized by the recommendations of The Saint Vincent Dec-
laration [38] which fixed in 1989 the following objectives:
– Reduce new blindness due to diabetes by one third or
more
– Reduce numbers of people entering end-stage diabetic
renal failure by at least one third
– Reduce by one half the rate of limb amputations for dia-
betic gangrene
– Cut morbidity and mortality from coronary disease in
the diabetic by vigorous programmes of risk factor
reduction
– Achieve pregnancy outcome in the diabetic woman that
approximates that of the non-diabetic woman.
However, although most of developed countries have
reacted by pragmatic measures, the trend remain globally
passive mainly because developing countries have been,
so far, satisfied with adopting national conventions and
adhering to international recommendations instead of
Table 3: Fixed point values (× 1O7) for the linear model using different values of l, I = 6 × 107, λ = 0.66
N+ N+ C+ C+
l yr Euler Method1 Euler Method1
0.01 6.08 6.08 4.75 4.75
0.02 6.11 6.11 4.77 4.77
0.05 6.11 6.11 4.7 4.7
0.1 6.11 6.11 4.7 4.7
0.2 6.11 6.11 4.7 4.7
0.5 6.11 6.11 4.7 4.7
1 6.11 6.11 4.7 4.7
2 6.11 6.11 4.7 4.7
2.5 div 6.11 div 4.7
3 div 6.11 div 4.7
3.5 div 6.11 div 4.7
4 div 6.11 div 4.7
div = divergence of numerical methods.BioMedical Engineering OnLine 2004, 3 http://www.biomedical-engineering-online.com/content/3/1/20
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working in the field. As stressed earlier, this behaviour can
be partly explained by lack of means and poor budget
affected to health care but, in general, bad management
and absence of goodwill assume a large part of responsi-
bility. The illustration yielded by our mathematical model
confirms the diagnosis and the recommendations given
by specialists and experts in the field of diabetes and
health management in general. Moreover, it gives to
health decision makers guide lines of comparison
between the social and economic costs of uncontrolled
diabetes, and the benefit gained by a productive invest-
ment in primary healthcare.
Conclusion
In this paper, a mathematical model was proposed to deal
with the dynamics of a population of diabetes. The model
was formalized by a system of ordinary differential equa-
tions, then numerical approximations were used to obtain
numerical results. Although linear and non-linear cases
were considered, for sake of clarity and simplicity, only
numerical results of the linear model were given.
The model showed clearly the results given according to
different scenarios. The main purpose was to stress the
importance to control the incidence of diabetes and its
complications and hence to convince decision makers
that investment in healthcare is a cost-effective strategy.
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Appendix
t : time,
l : increment in t (the time step),
C(t) : number of diabetics with complications,
D(t) : number of diabetics without complications,
N(t) : number of diabetics (N = C + D),
I(t) : incidence of diabetes mellitus,
J : jacobien,
µ : natural mortality rate,
λ : probability of developing a complication,
γ : rate at which complications are cured,
ν: rate at which patients with complications become
severely disabled,
δ : mortality rate due to complications,
θ = µ + δ + γ + ν,
χ1, χ2 : eigenvalues,
C0, N0 : initial values of C and N,
C*, N* : critical-point values of C and N,
C+, N+ : fixed-point values of C and N,
x: x = [C, N]T, T denoting transpose,
X0 : X0 = [C0, N0]T,
A : constant square matrix of order two (linear model),
b(t): b(t) = [0, I(t)]T,
Table 4: Output of the nine scenarios according to each level of incidence I and complications λ (× 107)
I λ LMH
L C = 0.72 C = 2.18 C = 4.36
N = 1.36 N = 4.09 N = 8.18
M C = 0.75 C = 0.22 C = 4.55
N = 1.20 N = 3.6 N = 7.21
H C = 0.79 C = 2.38 C = 4.77
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Cn, Nn : approximations to C(nl), N(nl),
Xn : Xn = [Cn, Nn]T,
In : In = I(nl).
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